Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ningbo Scientz Biotechnology CoBJSE:920685 73 EBITDA Margin % is 25.44% as of Mar. 2026, which is 32% below its 10-year median of 37.41. GuruFocus rates BJSE:920685 with a GF Score™ of 73/100 and a GF Value™ of ¥15.96 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 814 Medical Devices & Instruments companies, Ningbo Scientz Biotechnology Co ranks better than 88.7% on this metric.
Ningbo Scientz Biotechnology Co (BJSE:920685) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ningbo Scientz Biotechnology Co EBITDA Margin % Related Terms
Ningbo Scientz Biotechnology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ningbo Scientz Biotechnology Co EBITDA Margin % Chart
BJSE:920685 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Ningbo Scientz Biotechnology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ningbo Scientz Biotechnology Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ningbo Scientz Biotechnology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ningbo Scientz Biotechnology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ningbo Scientz Biotechnology Co (BJSE:920685) has a EBITDA Margin % of 25.44% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ningbo Scientz Biotechnology Co and its competitors. This is 32% below median its historical median of 37.41. Over the past decade, Ningbo Scientz Biotechnology Co's EBITDA Margin % has ranged from 28.35 to 49.19. According to the industry distribution chart, Ningbo Scientz Biotechnology Co ranks #92 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 11.3%.
Is Ningbo Scientz Biotechnology Co's EBITDA Margin % too high?
Ningbo Scientz Biotechnology Co's current EBITDA Margin % of 25.44% is 32% below median its 10-year median of 37.41. Over the past 10 years, this metric has ranged from a low of 28.35 to a high of 49.19. The Medical Devices & Instruments industry median EBITDA Margin % is 7.63. Ningbo Scientz Biotechnology Co's value of 25.44% is 233.6% above this industry median. Based on the distribution chart, Ningbo Scientz Biotechnology Co ranks #92 out of 814 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Ningbo Scientz Biotechnology Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ningbo Scientz Biotechnology Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ningbo Scientz Biotechnology Co ranks #92 out of 814 companies for EBITDA Margin %. This places Ningbo Scientz Biotechnology Co in the top 11% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.63. Ningbo Scientz Biotechnology Co's value of 25.44% is 233.6% above this benchmark. Historically, Ningbo Scientz Biotechnology Co's own EBITDA Margin % has ranged from 28.35 to 49.19 over the past decade. While the company's 10-year median is 37.41 vs. the industry median of 7.63, Ningbo Scientz Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.63, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ningbo Scientz Biotechnology Co's current EBITDA Margin % of 25.44% is 233.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ningbo Scientz Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ningbo Scientz Biotechnology Co's current EBITDA Margin % is 25.44%, which is 32% below median its own 10-year median of 37.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningbo Scientz Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Ningbo Scientz Biotechnology Co (BJSE:920685) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥15.96, compared to a current price of ¥12.18 — trading 23.7% below its estimated fair value. The current EBITDA Margin % is 25.44%, which is 32% below median its 10-year median of 37.41 and 233.6% above the Medical Devices & Instruments industry median of 7.63. Ningbo Scientz Biotechnology Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ningbo Scientz Biotechnology Co (BJSE:920685), the current EBITDA Margin % is 25.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ningbo Scientz Biotechnology Co (BJSE:920685) Overvalued in 2026?
Based on GuruFocus' analysis, Ningbo Scientz Biotechnology Co stock appears to be undervalued.
The current stock price of ¥12.18 is trading 23.7% below its estimated GF Value™ of ¥15.96.
GuruFocus considers Ningbo Scientz Biotechnology Co to be Modestly Undervalued.
Key valuation signals for BJSE:920685:
EBITDA Margin %: 25.44% (32% below median its 10-year median of 37.41)
GF Value™: ¥15.96 vs. price of ¥12.18 (23.7% below fair value)
Industry Position: 233.6% above the Medical Devices & Instruments median (#92 of 814)
No single metric tells the full story. See the BJSE:920685 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920685 has been successfully added to your 
